Triazabenzo[e]azulene derivatives for the treatment of tumors

专利摘要:

公开号:AU2007315374A1
申请号:U2007315374
申请日:2007-09-29
公开日:2008-05-08
发明作者:Christiane Amendt；Hartmut Greiner；Guenter Hoelzemann
申请人:Merck Patent GmbH；
IPC主号:C07D487-04

专利说明:
WO 2008/052628 PCT/E P12007/008494 TRlAZABENZO(E)AZULENE DERIVATIVES FOR THE TREATMENT OF TUMOURS BACKGROUND OF THE INVENTION The invention had the object of finding novel compounds having valuable properties, in particular those which can be used for the preparation of medicaments. The present invention relates to compounds and to the use of compounds in which the inhibition, regulation and/or modulation of signal transduction by kinases, in particular TGF-beta receptor kinases, plays a role, further more to pharmaceutical compositions which comprise these compounds, and to the use of the compounds for the treatment of kinase-induced dis eases. Transforming growth factor beta is the prototype of the TGF-beta super family, a family of highly preserved, pleiotropic growth factors, which carry out important functions both during embryo development and also in the adult organism. In mammals, three isoforms of TGF-beta (TGF beta 1, 2 and 3) have been identified, TGF-beta 1 being the commonest isoform (Kingsley (1994) Genes Dev 8:133-146). TGF-beta 3 is ex pressed, for example, only in mesenchymal cells, whereas TGF-beta 1 is found in mesenchymal and epithelial cells. TGF-beta is synthesised as pre-proprotein and is released in inactive form into the extracellular matrix (Derynck (1985) Nature 316: 701-705; Bottinger (1996) PNAS 93: 5877-5882). Besides the proregion cleaved off, which is also known as latency associated peptide (LAP) and remains associated with the mature region, one of the 4 isoforms of the latent TGF-beta binding proteins (LTBP 1-4) may also be bonded to TGF-beta (Gentry (1988) Mol Cell Biol 8: 4162-4168, Munger (1997) Kindey Int 51: 1376-1382). The activation of the inactive complex that is necessary for the develop ment of the biological action of TGF-beta has not yet been clarified in WO 2008/052628 PCT/E P2007/008494 -2 full. However, proteolytic processing, for example by plasmin, plasma transglutaminase or thrombospondin, is certainly necessary (Munger (1997) Kindey Int 51: 1376-1382). The activated ligand TGF-beta medi ates its biological action via three TGF-beta receptors on the mem brane, the ubiquitously expressed type I and type Il receptors and the type Ill receptors betaglycan and endoglin, the latter only being ex pressed in endothelial cells (Gougos (1990) J Biol Chem 264: 8361 8364, Loeps-Casillas (1994) J Cell Biol 124:557-568). Both type IlIl TGF 10 beta receptors lack an intracellular kinase domain which facilitates sig nal transmission into the cell. Since the type Ill TGF-beta receptors bind all three TGF-beta isoforms with high affinity and type 11 TGF-beta receptor also has higher affinity for ligands bonded to type Ill receptor, 15 the biological function is thought to consist in regulation of the availabil ity of the ligands for type I and type I TGF-beta receptors (Lastres (1996) J Cell Biol 133:1109-1121; Lopes-Casillas (1993) Cell 73: 1435 1344). The structurally closely related type I and type II receptors have a 20 serine/threonine kinase domain, which is responsible for signal trans mission, in the cytoplasmatic region. Type Il TGF-beta receptor binds TGF-beta, after which the type I TGF-beta receptor is recruited to this signal-transmitting complex. The serine/threonine kinase domain of the type 11 receptor is constitutively active and is able to phosphorylate seryl 25 radicals in this complex in the so-called GS domain of the type I recep tor. This phosphorylation activates the kinase of the type I receptor, which is now itself able to phosphorylate intracellular signal mediators, the SMAD proteins, and thus initiates intracellular signal transmission 30 (summarised in Derynck (1997) Biochim Biophys Acta 1333: F105 F150). The proteins of the SMAD family serve as substrates for all TGF-beta family receptor kinases. To date, 8 SMAD proteins have been identified, 35 which are divided into 3 groups: (1) receptor-associated SMADs (R-SMADs) are direct substrates of the TGF-P receptor kinases (SMAD1, 2, 3, 5, 8); (2) co-SMADs, which associate with the R-Smads WO 2008/052628 PCT/E 2007/0I08494 -3 during the signal cascade (SMAD4); and (3) inhibitory SMADs (SMAD6, 7), which inhibit the activity of the above-mentioned SMAD proteins. Of the various R-SMADs, SMAD2 and SMAD3 are the TGF-beta-specific 5 signal mediators. In the TGF-beta signal cascade, SMAD2/SMAD3 are thus phosphorylated by the type I TGF-beta receptor, enabling them to associate with SMAD4. The resultant complex of SMAD2/SMAD3 and SMAD4 can now be translocated into the cell nucleus, where it can initi ate the transcription of the TGF-beta-regulated genes directly or via 10 other proteins (summarised in Itoh (2000) Eur J Biochem 267: 6954 6967; Shi (2003) Cell 113: 685-700). The spectrum of the functions of TGF-beta is wide-ranging and depen dent on cell type and differentiation status (Roberts (1990) Handbook of 15 Experimental Pharmacology: 419-472). The cellular functions which are influenced by TGF-beta include: apoptosis, proliferation, differentiation, mobility and cell adhesion. Accordingly, TGF-beta plays an important role in a very wide variety of biological processes. During embryo 20 development, it is expressed at sites of morphogenesis and in particular in areas with epithelial-mesenchymal interaction, where it induces important differentiation processes (Pelton (1991) J Cell Biol 115:1091 1105). TGF-beta also carries out a key function in the self-renewal and maintenance of an undifferentiated state of stem cells (Mishra (2005) 25 Science 310: 68-71). In addition, TGF-beta also fulfils important func tions in the regulation of the immune system. It generally has an immunosuppressive action, since it inhibits, inter alia, the proliferation of lymphocytes and restricts the activity of tissue macrophages. TGF-beta 30 thus allows inflammatory reactions to subside again and thus helps to prevent excessive immune reactions (Bogdan (1993) Ann NY Acad Sci 685: 713-739, summarised in Letterio (1998) Annu Rev Immunol 16: 137-161). Another function of TGF-beta is regulation of cell proliferation. 35 TGF-beta inhibits the growth of cells of endothelial, epithelial and hae matopoietic origin, but promotes the growth of cells of mesenchymal origin (Tucker (1984) Science 226:705-707, Shipley (1986) Cancer Res WO 2008/052628 PCT/i P2007/008494 -4 46:2068-2071, Shipley (1985) PNAS 82: 4147-4151). A further impor tant function of TGF-beta is regulation of cellular adhesion and cell-cell interactions. TGF-beta promotes the build-up of the extracellular matrix 5 by induction of proteins of the extracellular matrix, such as, for example, fibronectin and collagen. In addition, TGF-beta reduces the expression of matrix-degrading metalloproteases and inhibitors of metalloproteases (Roberts (1990) Ann NY Acad Sci 580: 225-232; ignotz (1986) J Biol Chem 261: 4337-4345; Overall (1989) J Biol Chem 264: 1860-1869); 10 Edwards (1987) EMBO J 6: 1899-1904). The broad spectrum of action of TGF-beta implies that TGF-beta plays an important role in many physiological situations, such as wound heal ing, and in pathological processes, such as cancer and fibrosis. 15 TGF-beta is one of the key growth factors in wound healing (summa rised in O'Kane (1997) Int J Biochem Cell Biol 29: 79-89). During the granulation phase, TGF-beta is released from blood platelets at the site of injury. TGF-beta then regulates its own production in macrophages 20 and induces the secretion of other growth factors, for example by mono cytes. The most important functions during wound healing include stimulation of chemotaxis of inflammatory cells, the synthesis of extra cellular matrix and regulation of the proliferation, differentiation and gene expression of all important cell types involved in the wound-heal 25. ing process. Under pathological conditions, these TGF-beta-mediated effects, in par ticular the regulation of the production of extracellular matrix (ECM), can result in fibrosis or scars in the skin (Border (1994) N Engl J Med 30 331:1286-1292). For the fibrotic diseases, diabetic nephropathy and glomeronephritis, it has been shown that TGF-beta promotes renal cell hypertrophy and pathogenic accumulation of the extracellular matrix. Interruption of the 35 TGF-beta signalling pathway by treatment with anti-TGF-beta antibodies prevents expansion of the mesangial matrix, progressive reduction in kidney function and reduces established lesions of diabetic glomerulo- WO 2008/052628 PCT/EP2007/008494 -5 pathy in diabetic animals (Border (1990) 346: 371-374, Yu (2004) Kind ney Int 66: 1774-1784, Fukasawah (2004) Kindney Int 65: 63-74, Sharma (1996) Diabetes 45: 522-530). 5 TGF-beta also plays an important role in liver fibrosis. The activation, essential for the development of liver fibrosis, of the hepatic stellate cells to give myofibroblasts, the main producer of the extracellular matrix in the course of the development of liver cirrhosis, is stimulated by TGF beta. It has likewise been shown here that interruption of the TGF-beta 10 signalling pathway reduces fibrosis in experimental models (Yata (2002) Hepatology 35:1022-1030; Arias (2003) BMC Gastroenterol 3:29) TGF-beta also takes on a key function in the formation of cancer (sum marised in Derynck (2001) Nature Genetics: 29: 117-129; Elliott (2005) 15 J Clin Onc 23: 2078-2093). In early stages of the development of can cer, TGF-beta counters the formation of cancer. This tumour-suppres sive action is based principally on the ability of TGF-beta to inhibit the division of epithelial cells. By contrast, TGF-beta promotes cancer 20 growth and the formation of metastases in late tumour stages. This can be attributed to the fact that most epithelial tumours develop a resis tance to the growth-inhibiting action of TGF-beta, and TGF-beta simul taneously supports the growth of the cancer cells via other mechanisms. These mechanisms include promotion of angiogenesis, the immuno 25 suppressive action, which supports tumour cells in avoiding the control function of the immune system (immunosurveillance), and promotion of invasiveness and the formation of metastases. The formation of an invasive phenotype of the tumour cells is a principal prerequisite for the 30 formation of metastases. TGF-beta promotes this process through its ability to regulate cellular adhesion, motility and the formation of the extracellular matrix. Furthermore, TGF-beta induces the transition from an epithelial phenotype of the cell to the invasive mesenchymal pheno 35 type (epithelial mesenchymal transition = EMT). The important role played by TGF-beta in the promotion of cancer growth is also demon strated by investigations which show a correlation between strong TGF- WO 2008/052628 PCT/E P12007/008494 -6 beta expression and a poor prognosis. Increased TGF-beta level have been found, inter alia, in patients with prostate, breast, intestinal and lung cancer (Wikstrom (1998) Prostate 37: 19-29; Hasegawa (2001) 5 Cancer 91: 964-971; Friedman (1995), Cancer Epidemiol Biomarkers Prev. 4:549-54). Owing to the cancer-promoting actions of TGF-beta described above, inhi bition of the TGF-beta signalling pathway, for example via inhibition of the TGF-beta type I receptor, is a possible therapeutic concept. It has been 10 shown in numerous preclinical trials that interruption of the TGF-beta sig nalling pathway does indeed inhibit cancer growth. Thus, treatment with soluble TGF-beta type Il receptor reduces the formation of metastases in transgenic mice, which develop invasive breast cancer in the course of 15 time (Muraoka (2002) J Clin Invest 109: 1551-1559, Yang (2002) J Clin Invest 109: 1607-1615). Tumour cell lines which express a defective TGF-beta type 11 receptor exhibit reduced tumour and metastatic growth (Oft (1998) Curr Biol 8: 20 1243-1252, McEachern (2001) Int J Cancer 91:76-82, Yin (1999) Jclin Invest 103: 197-206). Conditions "characterised by increased TGF-p activity" include those in which TGF-P synthesis is stimulated so that TGF-3 is present at increased 25 levels or in which latent TGF-P protein is undesirably activated or con verted to active TGF-P protein or in which TGF-p receptors are upregu lated or in which the TGF-p protein shows enhanced binding to cells or the extracellular matrix in the location of the disease. Thus, in each case 30 "increased activity" refers to any condition in which the biological activity of TGF-p is undesirably high, regardless of the cause. A number of diseases have been associated with TGF-[1 overproduction. 35 WO 2008/052628 PCT/EP2007/008494 -7 Inhibitors of the intracellular TGF-p signalling pathway are suitable treat ments for fibroproliferative diseases. Specifically, fibroproliferative dis eases include kidney disorders associated with unregulated TGF-pi activity 5 and excessive fibrosis including glomerulonephritis (GN), such as mesan gial proliferative GN, immune GN and crescentic GN. Other renal condi tions include diabetic nephropathy, renal interstitial fibrosis, renal fibrosis in transplant patients receiving cyclosporin, and HIV-associated nephropathy. 10 Collagen vascular disorders include progressive systemic sclerosis, poly myositis, sclerodermatitis, dermatomyositis, eosinophilic fasciitis, morphea, or those associated with the occurrence of Raynaud's syndrome. Lung fibroses resulting from excessive TGF-p activity include adult respiratory distress syndrome, idiopathic pulmonary fibrosis, and interstitial pulmonary 15 fibrosis often associated with autoimmune disorders, such as systemic lupus erythematosus and sclerodermatitis, chemical contact or allergies. Another autoimmune disorder associated with fibroproliferative character istics is rheumatoid arthritis. 20 Eye diseases associated with a fibroproliferative condition include retinal reattachment surgery accompanying proliferative vitreoretinopathy, cata ract extraction with intraocular lens implantation, and post-glaucoma drain 25 age surgery and are associated with TGF-p1 overproduction. Fibrotic diseases associated with TGF-p1 overproduction can be divided into chronic conditions, such as fibrosis of the kidney, lung and liver, and more acute conditions, such as dermal scarring and restenosis (Chamber 30 lain, J. Cardiovascular Drug Reviews, 19(4): 329-344). Synthesis and secretion of TGF-p1 by tumour cells can also lead to immune suppression, as seen in patients with aggressive brain or breast tumours (Arteaga, et al. (1993) J. Clin. Invest. 92: 2569-2576). The course of leishmanial infection 35 in mice is drastically altered by TGF-P1 (Barral-Netto, et al. (1992) Science 257: 545-547). TGF-p1 exacerbated the disease, whereas TGF-01 anti- WO 2008/052628 PCT/EP2007/0084)4 bodies halted the progression of the disease in genetically susceptible mice. Genetically resistant mice became susceptible to leishmanial infec tion upon administration of TGF-p1. 5 The profound effects on extracellular matrix deposition have been reviewed (Rocco and Ziyadeh (1991) in Contemporary Issues in Nephrol ogy v.23, Hormones, autocoids and the kidney. ed. Jay Stein, Churchill Livingston, New York pp. 391-410; Roberts, et al. (1988) Rec. Prog. Hor 10 mone Res. 44: 157-197) and include stimulation of the synthesis and inhi bition of the degradation of extracellular matrix components. Since the structural and filtration properties of the glomerulus are largely determined by the extracellular matrix composition of the mesangium and glomerular 15 membrane, it is not surprising that TGF-p1 has profound effects on the kidney. The accumulation of mesangial matrix in proliferative glomerulo nephritis (Border, et al., (1990) Kidney Int. 37: 689-695) and diabetic nephropathy (Mauer, et al. (1984) J. Clin. Invest. 74: 1143-1155) are clear 20 and dominant pathological features of the diseases. TGF-p 1 levels are elevated in human diabetic glomerulosclerosis (advanced neuropathy) (Yamamoto, et al. (1993) Proc. Natl. Acad. Sci. 90: 1814-1818). TGF-p1 is an important mediator in the genesis of renal fibrosis in a number of ani 25 mal models (Phan, et al. (1990) Kidney Int. 37: 426; Okuda, et al. (1990) J. Clin. Invest. 86: 453). Suppression of experimentally induced glomerulo nephritis in rats has been demonstrated by antiserum against TGF-p1 (Border, et al. (1990) Nature 346: 371) and by an extracellular matrix pro tein, decorin, which can bind TGF-p1 (Border, et al. (1992) Nature 360: 30 361-363). Excessive TGF-1 leads to dermal scar-tissue formation. Neutralising TGF-P1 antibodies injected into the margins of healing wounds in rats has 35 been shown to inhibit scarring without interfering with the rate of wound healing or the tensile strength of the wound (Shah, et al. (1992) Lancet WO 2008/052628 PC:T/EPI2007/008494 -9 339: 213-214). At the same time there was reduced angiogenesis, a reduced number of macrophages and monocytes in the wound, and a reduced amount of disorganised collagen fibre deposition in the scar tis 5 sue. TGF-fp1 may be a factor in the progressive thickening of the arterial wall which results from the proliferation of smooth muscle cells and deposition of extracellular matrix in the artery after balloon angioplasty. The diameter 10 of the restenosed artery may be reduced by 90% by this thickening, and since most of the reduction in diameter is due to extracellular matrix rather than smooth muscle cell bodies, it may be possible to reopen these ves sels to 50% simply by reducing excessive extracellular matrix deposition. 15 In undamaged pig arteries transfected in vivo with a TGF-p11 gene, TGF-fpl gene expression was associated with both extracellular matrix synthesis and hyperplasia (Nabel, et al. (1993) Proc. Nati. Acad. Sci USA 90: 10759 10763). The TGF-p1-induced hyperplasia was not as extensive as that 20 induced with PDGF-BB, but the extracellular matrix was more extensive with TGF-P1 transfectants. No extracellular matrix deposition was associ ated with hyperplasia induced by FGF-1 (a secreted form of FGF) in this gene transfer pig model (Nabel (1993) Nature 362: 844-846). 25 There are various types of cancer where TGF-p1 produced by the tumour may be deleterious. MATLyLu rat prostate cancer cells (Steiner and Bar rack (1992) Mol. Endocrinol 6: 15-25) and MCF-7 human breast cancer cells (Arteaga, et al. (1993) Cell Growth and Differ. 4: 193-201) became 30 more tumorigenic and metastatic after transfection with a vector express ing the mouse TGF-p1. TGF-p1 has been associated with angiogenesis, metastasis and poor prognosis in human prostate and advanced intestinal cancer (Wikstrom, P., et al. (1988) Prostate 37; 19-29; Saito, H., et al. 35 (1999) Cancer 86: 1455-1462). In breast cancer, a poor prognosis is asso ciated with elevated TGF-p (Dickson, et al. (1987) Proc. Nati. Acad. Sci.
WO 2008/052628 PCT/EP2007/008494 - 10 USA 84: 837-841; Kasid, et al. (1987) Cancer Res. 47: 5733-5738; Daly, et al. (1990) J. Cell Biochem. 43: 199-211; Barrett-Lee, et al. (1990) Br. J. Cancer 61: 612-617; King, et al (1989) J. Steroid Biochem. 34: 133-138; 5 Welch, et al (1990) Proc. NatI. Acad. Sci USA 87: 7678-7682; Walker et al. (1992) Eur. J. Cancer 238: 641-644), and induction of TGF-p 1 by tamoxi fen treatment (Butta, et al. (1992) Cancer Res. 52: 4261-4264) has been associated with failure of tamoxifen treatment for breast cancer (Thomp son, et al. (1991) Br. J. Cancer 63: 609-614). Anti-TGF-p 1 antibodies 10 inhibit the growth of MDA-231 human breast cancer cells in athymic mice (Arteaga, et al. (1993) J. Clin. Invest. 92: 2569-2576), a treatment which is correlated with an increase in natural killer cell activity in the spleen. CHO cells transfected with latent TGF-p1 also showed decreased NK activity 15 and increased tumour growth in nude mice (Wallick, et al. (1990) J. Exp. Med. 172: 177-1784). Thus, TGF-p secreted by breast tumours may cause endocrine immune suppression. High plasma concentrations of TGF-i1 show a poor prognosis for advanced breast cancer patients (Anscher, et 20 al. (1993) N. Engl. J. Med. 328: 1592-1598). Patients with high circulating TGF-pi before high dose chemotherapy and autologous bone marrow transplantation are at high risk of a hepatic veno-occlusive disease (15 50% of all patients with a mortality rate up to 50%) and idiopathic inter 25 stitial pneumonitis (40 to 60% of all patients). The implication of these findings is 1) that elevated plasma levels of TGF-P1 can be used to identify at-risk patients and 2) that reduction of TGF-p1 can decrease the morbidity and mortality of these common treatments for breast cancer patients. 30 Many malignant cells secrete transforming growth factor P (TGF-P), a potent immunosuppressant, suggesting that TGF-P production may repre sent a significant tumour escape mechanism from host immunosurveil lance. Establishment of a leukocyte sub-population with a disrupted TGF-i signalling pathway in the tumour-bearing host offers a powerful measure for immunotherapy of cancer. A transgenic animal model with a disrupted WO 2008/052628 PCT/E P2007/008494 - 11 TGF-p signalling pathway in T cells is capable of eradicating a normally lethal TGF-p-overexpressing lymphoma tumour, EL4 (Gorelik and Flavell, (2001) Nature Medicine 7 (10): 1118-1122). Downregulation of TGF-p1 5 secretion in tumour cells results in restoration of immunogenicity in the host, while T-cell insensitivity to TGF-p results in accelerated differentiation and autoimmunity, elements of which may be required in order to combat self-antigen-expressing tumours in a tolerised host. The immunosuppres 10 sive effects of TGF-P have also been implicated in a sub-population of HIV patients with lower than predicted immune response based on their CD4/CD8 T cell counts (Garba, et al., J. Immunology (2002) 168: 2247 2254). A TGF-p-neutralising antibody was capable of reversing the effect in culture, indicating that TGF-p signalling pathway inhibitors may be suit 15 able in reversing the immune suppression present in this subset of HIV patients. During the earliest stages of carcinogenesis, TGF-fp1 can act as a potent 20 tumour suppressor and may mediate the actions of some chemopreventive agents. At a certain point during the development and progression of malignant neoplasms, tumour cells appear to escape from TGF-13-depend ent growth inhibition in parallel with the appearance of biologically active 25 TGF-11 in the microenvironment. The dual tumour suppression/tumour promotion roles of TGF-p have been most clearly elucidated in a trans genic system overexpressing TGF-P in keratinocytes. While the transgen ics were more resistant to formation of benign skin lesions, the rate of 30 metastatic conversion in the transgenics was dramatically increased (Cui, et al, (1996) Cell 86(4): 531-42). The production of TGF-131 by malignant cells in primary tumours appears to increase with advancing stages of tumour progression. Studies in many of the major epithelial cancers sug 35 gest that the increased production of TGF-3 by human cancers occurs as a relatively late event during tumour progression. Furthermore, this tumour-associated TGF-p provides the tumour cells with a selective WO 2008/052628 PCT/E P2007/008494 - 12 advantage and promotes tumour progression. The effects of TGF-3 on cell-cell and cell-stroma interactions results in a greater propensity for invasion and metastasis. Tumour-associated TGF-p may allow tumour 5 cells to escape from immunosurveillance since it is a potent inhibitor of the clonal expansion of activated lymphocytes. TGF-53 has also been shown to inhibit the production of angiostatin. Cancer therapeutic modalities, such as radiation therapy and chemotherapy, induce the production of activated 10 TGF-3 in the tumour, thereby selecting outgrowth of malignant cells that are resistant to TGF-p growth inhibitory effects. Thus, these anticancer treatments increase the risk and hasten the development of tumours with enhanced growth and invasiveness. In this situation, agents targeting TGF i-mediated signal transduction might be a very effective therapeutic strat 15 egy. The resistance of tumour cells to TGF-p has been shown to negate many of the cytotoxic effects of radiation therapy and chemotherapy, and the treatment-dependent activation of TGF-5i in the stroma may even be detrimental as it makes the microenvironment more conducive to tumour 20 progression and contributes to tissue damage leading to fibrosis. The development of TGF-p signal transduction inhibitors is likely to benefit the treatment of advanced cancer alone and in combination with other thera pies. 25 The compounds are suitable for the treatment of cancer and other condi tions influenced by TGF-5 by inhibiting TGF-p in a patient in need thereof by administration of the compound(s) to the patient. TGF-p is also suitable 30 against atherosclerotic (T.A. McCaffrey: TGF-pis and TGF-f3 Receptors in Atherosclerosis: Cytokine and Growth Factor Reviews 2000, 11, 103-114) and Alzheimer's diseases (Masliah, E.; Ho, G.; Wyss-Coray, T.: Functional Role of TGF-p in Alzheimer's Disease Microvascular Injury: Lessons from Transgenic Mice: Neurochemistry International 2001, 39, 393-400). 35 WO 2008/052628 PCT/EP2007/008494 -13 It has been found that the compounds according to the invention and salts thereof have very valuable pharmacological properties while being well tol erated. 5 In particular, they exhibit TGFp receptor I kinase-inhibiting properties. The compounds according to the invention preferably exhibit an advanta geous biological activity, which can easily be demonstrated in enzyme based assays, for example assays as described herein. In such enzyme 10 based assays, the compounds according to the invention preferably exhibit and cause an inhibiting effect, which is usually documented by IC 50 values in a suitable range, preferably in the micromolar range and more prefera bly in the nanomolar range. 15 As discussed herein, these signalling pathways are relevant for various diseases. Accordingly, the compounds according to the invention are useful in the prophylaxis and/or treatment of diseases that are dependent 20 on the said signalling pathways by interaction with one or more of the said signalling pathways. The present invention therefore relates to compounds according to the invention as promoters or inhibitors, preferably as inhibitors, of the signal ling pathways described herein. The invention therefore preferably relates 25 to compounds according to the invention as promoters or inhibitors, pref erably as inhibitors, of the TGFp signalling pathway. The present invention furthermore relates to the use of one or more com 30 pounds according to the invention in the treatment and/or prophylaxis of diseases, preferably the diseases described herein, that are caused, medi ated and/or propagated by an increased TGFp activity. 35 The present invention therefore relates to compounds according to the invention as medicaments and/or medicament active ingredients in the WO 2008/052628 PCT/EP2007/008494 - 14 treatment and/or prophylaxis of the said diseases and to the use of com pounds according to the invention for the preparation of a pharmaceutical for the treatment and/or prophylaxis of the said diseases as well as to a 5 method for the treatment of the said diseases comprising the administra tion of one or more compounds according to the invention to a patient in need of such an administration. The host or patient can belong to any mammalian species, for example a 10 primate species, particularly humans; rodents, including mice, rats and hamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are of interest for experimental investigations, providing a model for treatment of a human disease. 15 The susceptibility of a particular cell to treatment with the compounds ac cording to the invention can be determined by in-vitro testing. Typically, a culture of the cell is combined with a compound according to the invention 20 at various concentrations for a period of time which is sufficient to allow the active agents to induce cell death or to inhibit migration, usually between about one hour and one week. In-vitro testing can be carried out using cul tivated cells from a biopsy sample. The viable cells remaining after the treatment are then counted. 25 The dose varies depending on the specific compound used, the specific disease, the patient status, etc. A therapeutic dose is typically sufficient considerably to reduce the undesired cell population in the target tissue while the viability of the patient is maintained. The treatment is generally 30 continued until a considerable reduction has occurred, for example an at least about 50% reduction in the cell burden, and may be continued until essentially no more undesired cells are detected in the body. 35 For identification of a signal transduction pathway and for detection of interactions between various signal transduction pathways, various scien tists have developed suitable models or model systems, for example cell WO 2008/052628 PCT/E P2007/008494 - 15 culture models (for example Khwaja et al., EMBO, 1997, 16, 2783-93) and models of transgenic animals (for example White et al., Oncogene, 2001, 20, 7064-7072). For the determination of certain stages in the signal trans 5 duction cascade, interacting compounds can be utilised in order to modu late the signal (for example Stephens et al., Biochemical J., 2000, 351, 95 105). The compounds according to the invention can also be used as reagents for testing kinase-dependent signal transduction pathways in ani mals and/or cell culture models or in the clinical diseases mentioned in this application. Measurement of the kinase activity is a technique which is well known to the person skilled in the art. Generic test systems for the determination of 15 the kinase activity using substrates, for example histone (for example Alessi et al., FEBS Left. 1996, 399, 3, pages 333-338) or the basic myelin protein, are described in the literature (for example Carnpos-Gonzelez, R. and Glenney, Jr., J.R. 1992, J. Biol. Chem. 267, page 14535). 20 For the identification of kinase inhibitors, various assay systems are avail able. In the scintillation proximity assay (Sorg et al., J. of. Biomolecular Screening, 2002, 7, 11-19) and the flashplate assay, the radioactive phos 25 phorylation of a protein or peptide as substrate with yATP is measured. In the presence of an inhibitory compound, a decreased radioactive signal, or none at all, is detectable. Furthermore, homogeneous time-resolved fluo rescence resonance energy transfer (HTR-FRET) and fluorescence polari sation (FP) technologies are suitable as assay methods (Sills et al., J. of 30 Biomolecular Screening, 2002, 191-214). Other non-radioactive ELISA assay methods use specific phospho-anti bodies (phospho-ABs). The phospho-AB binds only the phosphorylated substrate. This binding can be detected by chemiluminescence using a 35 second peroxidase-conjugated anti-sheep antibody (Ross et al., 2002, Biochem. J., just about to be published, manuscript BJ20020786).
WO 2008/052628 PCT/EP2007/008494 - 16 PRIOR ART 5 Triazolo-1,5-benzodiazepines are known from DE 2 318 673. L. Kosychova et al. in Chemistry of Heterocyclic Compounds, Vol. 40, 811 815 (2004) describe other 5,6-dihydro-4H-1,2,4-triazolo-a]-1,5-benzo diazepines for combating tumours. V. Ambrogi et al. in J. Heterocyclic Chem. 31, 1349-1352 (1994) describe 10 sulfur-containing 4,5-dihydro-s-triazolo[3,4-d]-1,5-benzothiazepine deriva tives. V. Ambrogi et al. in 11 Farmaco 48, 665-676 (1993) describe 1,4-benzo thiazines and 1,5-benzothiazepines having an action on the central nerv 15 ous system. Other triazole derivatives are disclosed as TGF-beta inhibitors in WO 03/042211 Al. Still other triazole derivatives are known as TGF-beta inhibitors from 20 WO 2004/026307 Al. Bicyclic pyrrole derivatives are described as TGF-beta inhibitors in WO 02/094833. 25 SUMMARY OF THE INVENTION The invention relates to compounds of the formula I 30 - N
R
3 N N / 35 R1 R
R
2 WO 2008/052628 PCIT/IEP2007/008494 - 17 in which R4 denotes H, A, OH, OA, NO 2 , NH 2 , NHA, NA 2 , Hal, CN, A-COO, COOH, COOA or CONR 4
R
5 , 2 3 5 R , R each, independently of one another, denote H, A, alkenyl having 2-6 C atoms, alkynyl having 2-6 C atoms or Hal,
R
4 , R 5 each, independently of one another, denote H or A, A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, in which 1-7 H atoms may be replaced 10 by F, Hal denotes F, Cl, Br or I, and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios. 15 The invention also relates to the optically active forms (stereoisomers), the enantiomers, the racemates, the diastereomers and the hydrates and sol vates of these compounds. The term solvates of the compounds is taken 20 to mean adductions of inert solvent molecules onto the compounds which form owing to their mutual attractive force. Solvates are, for example, mono- or dihydrates or alkoxides. The term pharmaceutically usable derivatives is taken to mean, for exam ple, the salts of the compounds according to the invention and also so 25 called prodrug compounds. The term prodrug derivatives is taken to mean compounds according to the invention which have been modified by means of, for example. alkyl or acyl groups, sugars or oligopeptides and which are rapidly cleaved in the 30 organism to form the effective compounds according to the invention. These also include biodegradable polymer derivatives of the compounds according to the invention, as described, for example, in Int. J. Pharm. 115, 61-67 (1995). 35 The expression "effective amount" denotes the amount of a medicament or of a pharmaceutical active ingredient which causes in a tissue, system, WO 2008/052628 PCT/ EP2007/008494 -18 animal or human a biological or medical response which is sought or desired, for example, by a researcher or physician. In addition, the expression "therapeutically effective amount" denotes an 5 amount which, compared with a corresponding subject who has not received this amount, has the following consequence: improved treatment, healing, prevention or elimination of a disease, syn drome, condition, complaint, disorder or side-effects or also the reduction in the advance of a disease, complaint or disorder. 10 The expression "therapeutically effective amount" also encompasses the amounts which are effective for increasing normal physiological function. The invention also relates to the use of mixtures of the compounds accord 15 ing to the invention, for example mixtures of two diastereomers, for exam ple in the ratio 1:1, 1:2, 1:3, 1:4, 1:5, 1:10, 1.100 or 1:1000. These are particularly preferably mixtures of stereoisomeric compounds. 20 The invention relates to the compounds of the formula I and salts thereof and to a process for the preparation of compounds of the formula I and pharmaceutically usable derivatives, salts, solvates, tautomers and stereo isomers thereof, characterised in that 25 a) a compound of the formula II H S N 30 R1 in which R 1 and R 2 has the meaning indicated in Claim 1, is reacted with a compound of the formula Ill WO 2008/052628 PCT/E P2007/008494 - 19 -~N
R
3 | H ll N''NH2 0 5 in which R 3 has the meaning indicated in Claim 1, or 10 b) a radical R 1 is converted into another radical R 1 by cleaving an ether, and/or 15 a base or acid of the formula I is converted into one of its salts. Above and below, the radicals R 1 , R 2 and R 3 have the meanings indicated for the formula I, unless expressly indicated otherwise. 20 A denotes alkyl, is unbranched (linear) or branched, and has 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms. A preferably denotes methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also 25 pentyl, 1-, 2- or 3-methylbutyl, 1,1- , 1,2- or 2,2-dimethylpropyl, 1-ethyl propyl, hexyl, 1- , 2- , 3- or 4-methylpentyl, 1,1- , 1,2- , 1,3- , 2,2- , 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1 -ethyl-1 -methylpropyl, 1 -ethyl-2 methylpropyl, 1,1,2- or 1,2,2-trimethylpropyl, further preferably, for exam 30 ple, trifluoromethyl. A very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 C atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoro ethyl. 35 R' preferably denotes H, OH, OA, Hal, CN or A-COO.
WO 2008/052628 PCT/E P2007/008494 - 20 R2 preferably denotes H or A.
R
3 preferably denotes A. 5 Throughout the invention, all radicals which occur more than once may be identical or different, i.e. are independent of one another. The compounds of the formula I may have one or more chiral centres and therefore occur in various stereoisomeric forms. The formula I encom passes all these forms. 10 Accordingly, the invention relates, in particular, to the compounds of the formula I in which at least one of the said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds can be 15 expressed by the following sub-formulae la to Id, which conform to the formula I and in which the radicals not designated in greater detail have the meaning indicated for the formula I, but in which 20 in la R 1 denotes H, OH, OA, Hal, CN or A-COO; in lb R2 denotes H or A; in Ic R3 denotes A; 25 in Id R 1 denotes H, OH, OA, Hal, CN or A-COO, R2 denotes H or A,
R
3 denotes A, 30 A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which 1-5 H atoms may be replaced by F, Hal denotes F, Cl, Br or 1; 35 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
WO 2008/052628 PC/E P2007/008494 -21 The compounds of the formula I and also the starting materials for their preparation are, in addition, prepared by methods known per se, as 5 described in the literature (for example in the standard works, such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart), to be precise under reaction conditions which are known and suitable for the said reactions. Use can also be made here of variants known per se which are not mentioned here 10 in greater detail. The starting compounds of the formulae Il and IllI are generally known. If they are novel, however, they can be prepared by methods known per se. 15 Compounds of the formula I can preferably be obtained by reacting a compound of the formula 11 with a compound of the formula lil. The reaction is carried out in an inert solvent. Depending on the conditions 20 used, the reaction time is between a few minutes and 14 days, the reaction temperature is between about 0* and 160', normally between 200 and 1500, in particular between about 80* and about 1300. Suitable inert solvents are, for example, hydrocarbons, such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons, 25 such as trichloroethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform or dichloromethane; alcohols, such as methanol, ethanol. Iso propanol, n-propanol, n-butanol or tert-butanol; ethers, such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; glycol ethers, 30 such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); ketones, such as acetone or butanone; amides, such as acetamide, dimethylacetamide, 1-methylpyrrolidinone (NMP) or dimethylformamide (DMF); nitriles, such as acetonitrile; sulfoxides, such as 35 dimethyl sulfoxide (DMSO); carbon disulfide; carboxylic acids, such as formic acid or acetic acid; nitro compounds, such as nitromethane or nitro benzene; esters, such as ethyl acetate, or mixtures of the said solvents.
WO 2008/052628 -22-PCT/E'2007/008494 - 22 Particular preference is given to n-butanol, NMP and/or DMF. Suitable for the cleavage of ethers is treatment with boron tribromide under 5 standard conditions. Pharmaceutical salts and other forms The said compounds according to the invention can be used in their final non-salt form. On the other hand, the present invention also encompasses 10 the use of these compounds in the form of their pharmaceutically accept able salts, which can be derived from various organic and inorganic acids and bases by procedures known in the art. Pharmaceutically acceptable salt forms of the compounds according to the invention are for the most 15 part prepared by conventional methods. If the compound according to the invention contains a carboxyl group, one of its suitable salts can be formed by reacting the compound with a suitable base to give the corresponding base-addition salt. Such bases are, for example, alkali metal hydroxides, 20 including potassium hydroxide, sodium hydroxide and lithium hydroxide; alkaline earth metal hydroxides, such as barium hydroxide and calcium hydroxide; alkali metal alkoxides, for example potassium ethoxide and sodium propoxide; and various organic bases, such as piperidine, di ethanolamine and N-methylglutamine. The aluminium salts of the com 25 pounds according to the invention are likewise included. In the case of certain compounds according to the invention, acid-addition salts can be formed by treating these compounds with pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides, such as hydro 30 gen chloride, hydrogen bromide or hydrogen iodide, other mineral acids and corresponding salts thereof, such as sulfate, nitrate or phosphate and the like, and alkyl- and monoarylsulfonates, such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and other organic acids and cor 35 responding salts thereof, such as acetate, trifluoroacetate, tartrate, maleate, succinate, citrate, benzoate, salicylate, ascorbate and the like. Accordingly, pharmaceutically acceptable acid-addition salts of the com- WO 2008/052628 P'C'T/EI '2007/008494 - 23 pounds according to the invention include the following: acetate, adipate, alginate, arginate, aspartate, benzoate, benzenesulfonate (besylate), bi sulfate, bisulfite, bromide, butyrate, camphorate, camphorsulfonate, 5 caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, diglu conate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethane sulfonate, fumarate, galacterate (from mucic acid), galacturonate, gluco heptanoate, gluconate, glutamate, glycerophosphate, hemisuccinate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydro 10 bromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, iso butyrate, lactate, lactobionate, malate, maleate, malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydrogenphos phate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmo 15 ate, pectinate, persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate, but this does not represent a restriction. Furthermore, the base salts of the compounds according to the invention 20 include aluminium, ammonium, calcium, copper, iron(Ill), iron(II), lithium, magnesium, manganese(ll), manganese(ll), potassium, sodium and zinc salts, but this is not intended to represent a restriction. Of the above-men tioned salts, preference is given to ammonium; the alkali metal salts so dium and potassium, and the alkaline earth metal salts calcium and mag 25 nesium. Salts of the compounds according to the invention which are derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines, also including naturally occurring substituted amines, cyclic amines, and basic 30 ion exchanger resins, for example arginine, betaine, caffeine, chloro procaine, choline, N,N'-dibenzylethylenediamine (benzathine), dicyclo hexylamine, diethanolamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, 35 N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D glucamine, morpholine, piperazine. piperidine, polyamine resins, procaine, WO 2008/052628 PCT/EP2007/008494 - 24 purines, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris(hydroxymethyl)methylamine (tromethamine), but this is not intended to represent a restriction. 5 Compounds of the present invention which contain basic nitrogen-con taining groups can be quaternised using agents such as (C 1 -C4)alkyl hal ides, for example methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; di(C1-C 4 )alkyl sulfates, for example dimethyl, diethyl and diamyl 10 sulfate; (C 1 o-C 18 )alkyl halides, for example decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; and aryl(C 1
-C
4 )alkyl halides, for example benzyl chloride and phenethyl bromide. Both water- and oil-solu ble compounds according to the invention can be prepared using such 15 salts. The above-mentioned pharmaceutical salts which are preferred include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisucci 20 nate, hippurate, hydrochloride, hydrobromide, isethionate, mandelate, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and trometh amine, but this is not intended to represent a restriction. 25 The acid-addition salts of basic compounds of the compounds according to the invention are prepared by bringing the free base form into contact with a sufficient amount of the desired acid, causing the formation of the salt in a conventional manner. The free base can be regenerated by 30 bringing the salt form into contact with a base and isolating the free base in a conventional manner. The free base forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as solubility in polar solvents; for the purposes of the 35 invention, however, the salts otherwise correspond to the respective free base forms thereof.
WO 2008/052628 PCI/E P2007/008494 - 25 As mentioned, the pharmaceutically acceptable base-addition salts of the compounds according to the invention are formed with metals or amines, such as alkali metals and alkaline earth metals or organic amines. Pre 5 ferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine. The base-addition salts of acidic compounds according to the invention are 10 prepared by bringing the free acid form into contact with a sufficient amount of the desired base, causing the formation of the salt in a conven tional manner. The free acid can be regenerated by bringing the salt form into contact with an acid and isolating the free acid in a conventional man 15 ner. The free acid forms differ in a certain respect from the corresponding salt forms thereof with respect to certain physical properties, such as soli bility in polar solvents; for the purposes of the invention, however, the salts otherwise correspond to the respective free acid forms thereof. 20 If a compound according to the invention contains more than one group which is capable of forming pharmaceutically acceptable salts of this type, the invention also encompasses multiple salts. Typical multiple salt forms include, for example, bitartrate, diacetate, difumarate, dimeglumine, di 25 phosphate, disodium and trihydrochloride, but this is not intended to repre sent a restriction. With regard to that stated above, it can be seen that the expression 30 'pharmaceutically acceptable salt" in the present connection is taken to mean an active ingredient which comprises a compound according to the invention in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared 35 with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first WO 2008/052628 PCT/E P2107/008494 - 26 time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body. 5 The invention furthermore relates to medicaments comprising at least one compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants. 10 Pharmaceutical formulations can be administered in the form of dosage units which comprise a predetermined amount of active ingredient per dosage unit. Such a unit can comprise, for example, 0.5 mg to 1 g, pref 15 erably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, of a com pound according to the invention, depending on the condition treated, the method of administration and the age, weight and condition of the patient, or pharmaceutical formulations can be administered in the form of dosage 20 units which comprise a predetermined amount of active ingredient per dosage unit. Preferred dosage unit formulations are those which comprise a daily dose or part-dose, as indicated above, or a corresponding fraction thereof of an active ingredient. Furthermore, pharmaceutical formulations of this type can be prepared using a process which is generally known in 25 the pharmaceutical art. Pharmaceutical formulations can be adapted for administration via any desired suitable method, for example by oral (including buccal or sublin 30 gual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) methods. Such formulations can be prepared using all processes known in the pharmaceutical art by, for example, combining the 35 active ingredient with the excipient(s) or adjuvant(s).
WO 2008/052628 ic'r/E P2007/008494 - 27 Pharmaceutical formulations adapted for oral administration can be administered as separate units, such as, for example, capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous 5 liquids; edible foams or foam foods; or oil-in-water liquid emulsions or water-in-oil liquid emulsions. Thus, for example, in the case of oral administration in the form of a tablet or capsule, the active-ingredient component can be combined with an oral, 10 non-toxic and pharmaceutically acceptable inert excipient, such as, for example, ethanol, glycerol, water and the like. Powders are prepared by comminuting the compound to a suitable fine size and mixing it with a pharmaceutical excipient comminuted in a similar manner, such as, for 15 example, an edible carbohydrate, such as, for example, starch or mannitol. A flavour, preservative, dispersant and dye may likewise be present. Capsules are produced by preparing a powder mixture as described above 20 and filling shaped gelatine shells therewith. Glidants and lubricants, such as, for example, highly disperse silicic acid, talc, magnesium stearate, cal cium stearate or polyethylene glycol in solid form, can be added to the powder mixture before the filling operation. A disintegrant or solubiliser, such as, for example, agar-agar, calcium carbonate or sodium carbonate, 25 may likewise be added in order to improve the availability of the medica ment after the capsule has been taken. In addition, if desired or necessary, suitable binders, lubricants and dis 30 integrants as well as dyes can likewise be incorporated into the mixture. Suitable binders include starch, gelatine, natural sugars, such as, for example, glucose or beta-lactose, sweeteners made from maize, natural and synthetic rubber, such as, for example, acacia, tragacanth or sodium 35 alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like. The lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium WO 2008/052628 PCT/E P2007/008494 - 28 chloride and the like. The disintegrants include, without being restricted thereto, starch, methylcellulose, agar, bentonite, xanthan gum and the like. The tablets are formulated by, for example, preparing a powder mixture, 5 granulating or dry-pressing the mixture, adding a lubricant and a disinteg rant and pressing the entire mixture to give tablets. A powder mixture is prepared by mixing the compound comminuted in a suitable manner with a diluent or a base, as described above, and optionally with a binder, such as, for example, carboxymethylcellulose, an alginate, gelatine or polyvinyl 10 pyrrolidone, a dissolution retardant, such as, for example, paraffin, an absorption accelerator, such as, for example, a quaternary salt, and/or an absorbant, such as, for example, bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting it with a binder, such as, 15 for example, syrup, starch paste, acadia mucilage or solutions of cellulose or polymer materials and pressing it through a sieve. As an alternative to granulation, the powder mixture can be run through a tableting machine, giving lumps of non-uniform shape, which are broken up to form granules. 20 The granules can be lubricated by addition of stearic acid, a stearate salt, talc or mineral oil in order to prevent sticking to the tablet casting moulds. The lubricated mixture is then pressed to give tablets. The compounds according to the invention can also be combined with a free-flowing inert excipient and then pressed directly to give tablets without carrying out the 25 granulation or dry-pressing steps. A transparent or opaque protective layer consisting of a shellac sealing layer, a layer of sugar or polymer material and a gloss layer of wax may be present. Dyes can be added to these coatings in order to be able to differentiate between different dosage units. 30 Oral liquids, such as, for example, solution, syrups and elixirs, can be pre pared in the form of dosage units so that a given quantity comprises a pre specified amount of the compound. Syrups can be prepared by dissolving 35 the compound in an aqueous solution with a suitable flavour, while elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be for mulated by dispersion of the compound in a non-toxic vehicle. Solubilisers WO 2008/052628 PCT/EP2007/008494 -29 and emulsifiers, such as, for example, ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavour additives, such as, for example, peppermint oil or natural sweeteners or saccharin, or other 5 artificial sweeteners and the like, can likewise be added. The dosage unit formulations for oral administration can, if desired, be en capsulated in microcapsules. The formulation can also be prepared in such a way that the release is extended or retarded, such as, for example, 10 by coating or embedding of particulate material in polymers, wax and the like. The compounds according to the invention and salts, solvates and physio 15 logically functional derivatives thereof can also be administered in the form of liposome delivery systems, such as, for example, small unilamellar vesi cles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from various phospholipids, such as, for example, cholesterol, 20 stearylamine or phosphatidylcholines. The compounds according to the invention and the salts, solvates and physiologically functional derivatives thereof can also be delivered using monoclonal antibodies as individual carriers to which the compound mole 25 cules are coupled. The compounds can also be coupled to soluble poly mers as targeted medicament carriers. Such polymers may encompass polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamido phenol, polyhydroxyethylaspartamidophenol or polyethylene oxide poly 30 lysine, substituted by palmitoyl radicals. The compounds may furthermore be coupled to a class of biodegradable polymers which are suitable for achieving controlled release of a medicament, for example polylactic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, poly 35 acetals, polydihydroxypyrans, polycyanoacrylates and crosslinked or amphipathic block copolymers of hydrogels.
WO 2008/052628 PCT/E P2(107/008494 - 30 Pharmaceutical formulations adapted for transdermal administration can be administered as independent plasters for extended, close contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis, as described in general terms in Pharmaceutical Research, 3(6), 318 (1986). Pharmaceutical compounds adapted for topical administration can be for mulated as ointments, creams, suspensions, lotions, powders, solutions, 10 pastes, gels, sprays, aerosols or oils. For the treatment of the eye or other external tissue, for example mouth and skin, the formulations are preferably applied as topical ointment or 15 cream. In the case of formulation to give an ointment, the active ingredient can be employed either with a paraffinic or a water-miscible cream base. Alternatively, the active ingredient can be formulated to give a cream with an oil-in-water cream base or a water-in-oil base. 20 Pharmaceutical formulations adapted for topical application to the eye include eye drops, in which the active ingredient is dissolved or suspended in a suitable carrier, in particular an aqueous solvent. 25 Pharmaceutical formulations adapted for topical application in the mouth encompass lozenges, pastilles and mouthwashes. Pharmaceutical formulations adapted for rectal administration can be 30 administered in the form of suppositories or enemas. Pharmaceutical formulations adapted for nasal administration in which the carrier substance is a solid comprise a coarse powder having a particle 35 size, for example, in the range 20-500 microns, which is administered in the manner in which snuff is taken, i.e. by rapid inhalation via the nasal passages from a container containing the powder held close to the nose.
WO 2008/052628 PCT/EP2007/008494 - 31 Suitable formulations for administration as nasal spray or nose drops with a liquid as carrier substance encompass active-ingredient solutions in water or oil. 5 Pharmaceutical formulations adapted for administration by inhalation encompass finely particulate dusts or mists, which can be generated by various types of pressurised dispensers with aerosols, nebulisers or insuf flators. 10 Pharmaceutical formulations adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray formulations. 15 Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions comprising antioxi dants, buffers, bacteriostatics and solutes, by means of which the formula 20 tion is rendered isotonic with the blood of the recipient to be treated: and aqueous and non-aqueous sterile suspensions, which may comprise sus pension media and thickeners. The formulations can be administered in single-dose or multidose containers, for example sealed ampoules and vials, and stored in freeze-dried lyophilisedd) state, so that only the addition 25 of the sterile carrier liquid, for example water for injection purposes, imme diately before use is necessary. Injection solutions and suspensions pre pared in accordance with the recipe can be prepared from sterile powders, granules and tablets. 30 It goes without saying that, in addition to the above particularly mentioned constituents, the formulations may also comprise other agents usual in the art with respect to the particular type of formulation; thus, for example, 35 formulations which are suitable for oral administration may comprise fla vours.
WO 2008/052628 PCT/F.P2007/008494 - 32 A therapeutically effective amount of a compound according to the inven tion depends on a number of factors, including, for example, the age and weight of the animal, the precise condition that requires treatment, and its 5 severity, the nature of the formulation and the method of administration, and is ultimately determined by the treating doctor or vet. However, an effective amount of a compound according to the invention for the treat ment of neoplastic growth, for example colon or breast carcinoma, is gen erally in the range from 0.1 to 100 mg/kg of body weight of the recipient 10 (mammal) per day and particularly typically in the range from 1 to 10 mg/kg of body weight per day. Thus, the actual amount per day for an adult mammal weighing 70 kg is usually between 70 and 700 mg, where this amount can be administered as a single dose per day or usually in a series 15 of part-doses (such as, for example, two, three, four, five or six) per day, so that the total daily dose is the same. An effective amount of a salt or solvate or of a physiologically functional derivative thereof can be deter mined as the fraction of the effective amount of the compound according 20 to the invention per se. It can be assumed that similar doses are suitable for the treatment of the other conditions mentioned above. The invention furthermore relates to medicaments comprising at least one compound according to the invention and/or pharmaceutically usable deri 25 vatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient. The invention also relates to a set (kit) consisting of separate packs of 30 (a) an effective amount of a compound according to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and 35 (b) an effective amount of a further medicament active ingredient.
WO 2008/052628 PCTI/EP2007/008494 -33 The set comprises suitable containers, such as boxes, individual bottles, bags or ampoules. The set may, for example, comprise separate ampoules, each containing an effective amount of a compound according 5 to the invention and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and an effective amount of a further medicament active ingredient in dis solved or lyophilised form. 10 USE The compounds according to the invention and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including 15 mixtures thereof in all ratios, are suitable as pharmaceutical active ingredients for mammals, in particu lar for humans, for the preparation of a medicament for the treatment and/or combating of cancer, tumour growth, metastatic growth, fibrosis, restenosis, HIV infection, Alzheimer's, atherosclerosis and/or for promoting 20 wound healing. Particular preference is given to the use for the treatment of a disease, where the disease is a solid tumour. 25 The solid tumour is preferably selected from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, 30 the larynx and/or the lung. The solid tumour is furthermore preferably selected from the group lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblas tomas, colon carcinoma and breast carcinoma. 35 WO 2008/052628 PCT/E"P2007/008494 - 34 Preference is furthermore given to the use for the treatment of a tumour of the blood and immune system, preferably for the treatment of a tumour selected from the group of acute myeloid leukaemia, chronic myeloid leu 5 kaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia. The present compounds are also suitable for combination with known anti cancer agents. These known anticancer agents include the following. oes trogen receptor modulators, androgen receptor modulators, retinoid recep 10 tor modulators, cytotoxic agents, antiproliferative agents, prenyl-protein transferase inhibitors, HMG-CoA reductase inhibitors, HIV protease inhibi tors, reverse transcriptase inhibitors and further angiogenesis inhibitors. The present compounds are particularly suitable for administration at the 15 same time as radiotherapy. The synergistic effects of inhibiting VEGF in combination with radiotherapy have been described in the art (see WO 00/61186). "Oestrogen receptor modulators" refers to compounds which interfere with 20 or inhibit the binding of oestrogen to the receptor, regardless of mecha nism. Examples of oestrogen receptor modulators include, but are not lim ited to, tamoxifen, raloxifene, idoxifene, LY353381, LY 117081, toremi fene, fulvestrant, 4-[7-(2,2-dimethyl-1-oxopropoxy-4-methyl-2-[4-[2-(1 piperidinyl)ethoxy]phenyl]-2H-1-benzopyran-3-yl]phenyl 2,2-dimethyl 25 propanoate, 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone and SH646. "Androgen receptor modulators" refers to compounds which interfere with or inhibit the binding of androgens to the receptor, regardless of mecha 30 nism. Examples of androgen receptor modulators include finasteride and other 5c-reductase inhibitors, nilutamide, flutamide, bicalutamide, liarozole and abiraterone acetate. "Retinoid receptor modulators" refers to compounds which interfere with or 35 inhibit the binding of retinoids to the receptor, regardless of mechanism. Examples of such retinoid receptor modulators include bexarotene, treti- WO 2008/052628 PCT/E P2007/008494 - 35 noin, 13-cis-retinoic acid, 9-cis-retinoic acid, a-difluoromethylornithine, ILX23-7553, trans-N-(4'-hydroxyphenyl)retinamide and N-4-carboxyphenyl retinamide. 5 'Cytotoxic agents" refers to compounds which result in cell death primarily through direct action on the cellular function or inhibit or interfere with cell myosis, including alkylating agents, tumour necrosis factors, intercalators, microtubulin inhibitors and topoisomerase inhibitors. Examples of cytotoxic agents include, but are not limited to, tirapazimine, 10 sertenef, cachectin, ifosfamide, tasonermin, lonidamine, carboplatin, altret amine, prednimustine, dibromodulcitol, ranimustine, fotemustine, neda platin, oxaliplatin, temozolomide, heptaplatin, estramustine, improsulfan tosylate, trofosfamide, nimustine, dibrospidium chloride, pumitepa, loba 15 platin, satraplatin, profiromycin, cisplatin, irofulven, dexifosfamide, cis aminedichloro(2-methylpyridine)platinum, benzylguanine, glufosfamide, GPX100, (trans,trans,trans)bis-mu-(hexane-1,6-diamine)-mu-[diamine platinum(Il)]bis[diamine(chloro)platinum(ll)] tetrachloride, diarizidinyl 20 spermine, arsenic trioxide, 1 -(11 -dodecylamino-1 0-hydroxyundecyl)-3,7 dimethylxanthine, zorubicin, idarubicin, daunorubicin, bisantrene, mitoxan trone, pirarubicin, pinafide, valrubicin, amrubicin, antineoplaston, 3-de amino-3'-morpholino-1 3-deoxo-1 0-hydroxycarminomycin, annamycin, gala rubicin, elinafide, MEN10755 and 4-demethoxy-3-deamino-3-aziridinyl-4 25 methylsulfonyldaunorubicin (see WO 00/50032). Examples of microtubulin inhibitors include paclitaxel, vindesine sulfate, 3',4'-didehydro-4'-deoxy-8'-norvincaleukoblastine, docetaxol, rhizoxin, dolastatin, mivobulin isethionate, auristatin, cemadotin, RPR109881, 30 BMS184476, vinflunine, cryptophycin, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4 methoxyphenyl)benzenesulfonamide, anhydrovinblastine, N,N-dimethyl-L valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, TDX258 and BMS188797. 35 Topoisomerase inhibitors are, for example, topotecan, hycaptamine, in notecan, rubitecan, 6 -ethoxypropionyl-3',4'-O-exobenzylidenechartreusin, WO 2008/052628 PCT/E P2007/008494 - 36 9-methoxy-N, N-dimethyl-5-nitropyrazolo[3,4,5-kl]acridine-2-(6H)propan amine, 1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H benzo[de]pyrano[3',4':b,7]indolizino[1,2b]quinoline-1 0,1 3(9H, 1 5H)-dione, 5 lurtotecan, 7-[2-(N-isopropylamino)ethyl]-(20S)camptothecin, BNP1350, BNP11100, BN80915, BN80942, etoposide phosphate, teniposide, sobu zoxane, 2'-dimethylamino-2'-deoxyetoposide, GL331, N-[2-(dimethyl amino)ethyl]-9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-1 -carbox amide, asulacrine, (5a,5aB,8aa,9b)-9-[2-[N-[2-(dimethylamino)ethyl]-N 10 methylamino]ethyl]-5-[4-hydroxy-3,5-dimethoxyphenyl]-5,5a,6,8,8a,9-hexo hydrofuro(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6-one, 2,3-(methylenedioxy) 5-methyl-7-hydroxy-8-methoxybenzo[c]phenanthridinium, 6,9-bis[(2-amino ethyl)amino]benzo[g]isoquinoline-5,10-dione, 5-(3-aminopropylamino) 15 7,1 0-dihydroxy-2-(2-hydroxyethylaminomethyl)-6H-pyrazolo[4,5, 1-del acridin-6-one, N-[1-[2(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thio xanthen-4-ylmethyl]formamide, N-(2-(dimethylamino)ethyl)acridine-4-car boxamide, 6-[[2-(dimethylamino)ethyl]amino]-3-hydroxy-7H-indeno[2,1 20 c]quinolin-7-one and dimesna. "Antiproliferative agents" include antisense RNA and DNA oligonucleotides such as G3139, ODN698, RVASKRAS, GEM231 and INX3001 and anti metabolites such as enocitabine, carmofur, tegafur, pentostatin, doxifluri dine, trimetrexate, fludarabine, capecitabine, galocitabine, cytarabine 25 ocfosfate, fosteabine sodium hydrate, raltitrexed, paltitrexid, emitefur, tiazofurin, decitabine, nolatrexed, pemetrexed, nelzarabine, 2'-deoxy-2' methylidenecytidine, 2'-fluoromethylene-2'-deoxycytidine, N-[5-(2,3 dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea, N6-[4-deoxy-4 30 [N2-[2(E),4(E)-tetradecadienoyl]glycylamino]-L-glycero-B-L-mannohepto pyranosyl]adenine, aplidine, ecteinascidin, troxacitabine, 4-[2-amino-4-oxo 4,6,7,8-tetrahydro-3H-pyrimidino[5,4-b]-1,4-thiazin-6-yl-(S)-ethyl]-2,5-thie noyl-L-glutamic acid, aminopterin, 5-fluorouracil, alanosine, 11 -acetyl-8 35 (carbamoyloxymethyl)-4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo (7.4.1.0.0)tetradeca-2,4,6-trien-9-ylacetic acid ester, swainsonine, lome trexol, dexrazoxane, methioninase, 2'-cyano-2'-deoxy-N4-palmitoyl-1-B-D- WO 2008/052628 PCT/E P2007/008494 - 37 arabinofuranosyl cytosine and 3-aminopyridine-2-carboxaldehyde thio semicarbazone. "Antiproliferative agents" also include monoclonal anti bodies to growth factors other than those listed under "angiogenesis 5 inhibitors", such as trastuzumab, and tumour suppressor genes, such as p53, which can be delivered via recombinant virus-mediated gene transfer (see US Patent No. 6,069,134, for example). In-vitro (enzyme) assay for determination of the efficacy of 10 the inhibitors of the inhibition of TGF-beta-mediated effects As an example, the ability of the inhibitors to eliminate TGF-beta-mediated growth inhibition is tested. 15 Cells of the lung epithelial cell line Mvl Lu are sown in a defined cell density in a 96-well microtitre plate and cultivated overnight under stan dard conditions. Next day, the medium is replaced by medium which comprises 0.5% of FCS and 1 ng/ml of TGF-beta, and the test sub 20 stances are added in defined concentrations, generally in the form of dilution series with 5-fold steps. The concentration of the solvent DMSO is constant at 0.5%. After a further two days, Crystal Violet staining of the cells is carried out. After extraction of the Crystal Violet from the fixed cells, the absorption is measured spectrophotometrically at 25 550 nm. It can be used as a quantitative measure of the adherent cells present and thus of the cell proliferation during the culture. Table 1: Inhibition of TGF-beta 30 Compound No.
IC
50 [mol/l] "Al" 3.9 E-06 "A2" 0.2 E-06 "A4"1 9.9 E-06 35 "A18" 3.3 E-06 WO 2008/052628 PCT/EP2007/00494 -38 "Al 9" 2.5 E-06 5 Cellular assay for testing TGF-beta receptor I kinase inhibitors The kinase assay is carried out as 384-well flashplate assay. 10 31.2 nM of GST-ALK5, 439 nM of GST-SMAD2 and 3 mM of ATP (with 0.3pCi of 1 3 P-ATP/well) are incubated in a total volume of 35pl (20 mM of HEPES, 10 mM of MgCl, 5 mM of MnCI, 1 mM of DTT, 0.1% of BSA, pH 7.4) without or with test substance (5-10 concentrations) at 300C for 15 45 min. The reaction is stopped using 25pl of 200 mM EDTA solution, fil tered with suction at room temperature after 30 min, and the wells are washed with 3 times 100 pl of 0.9% NaCl solution. Radioactivity is meas ured in the TopCount. The IC50 values are calculated using RS1. 20 Above and below, all temperatures are indicated in OC. In the following examples, "conventional work-up" means: water is added if necessary, the pH is adjusted, if necessary, to values between 2 and 10, depending on the constitution of the end product, the mixture is extracted with ethyl ace 25 tate or dichloromethane, the phases are separated, the organic phase is dried over sodium sulfate and evaporated, and the product is purified by chromatography on silica gel and/or by crystallisation. Rf values on silica gel; eluent: ethyl acetate/methanol 9:1. Mass spectrometry (MS): El (electron impact ionisation) M+ 30 FAB (fast atom bombardment) (M+H)+ ESI (electrospray ionisation) (M+H)* APCI-MS (atmospheric pressure chemical ionisation - mass spectrometry) (M+H)*. 35 WO 2008/052628 PCT/EPI2007/008494 - 39 Retention time R, [mini: Determination is carried out by HPLC Column: Chromolith SpeedROD, 50 x 4.6 mm2 (Order No. 1.51450.0001) from Merck 5 Gradient: 5.0 min, t = 0 min, A:B = 95:5, t = 4.4 min: A:B = 25:75, t = 4.5 min to t = 5.0 min: A:B = 0:100 Flow rate: 3.00 ml/min Eluent A: water + 0.1% of TFA (trifluoroacetic acid), 10 Eluent B: acetonitrile + 0.08% of TFA Wavelength: 220 nm General synthesis scheme: 15 0 N OH 0 15 NH 2 0H PPA N IR c~ R ----- cI 2.-,3-,4-Methyltetralone H o H] 0 20 HNO 3
/H
2 S0 4 N Reduction N 0 2 N R H 2 N R Sandmeyer or H 0 H S Balz-Schiemann N Lawesson N 25 R R R R N N 30 N Instead of the nitration (HNO 3
/H
2 SO4), bromination is also possible with subsequent exchange by CN or OMe (see Examples). 35 WO 2008/052628 PCT/EP2007/008494 -40 Example 1 Preparation of 8-methoxy-4-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro 5 4H-2,3,10b-triazabenz[e]azulene ("A 1") 1.1 1.00 g of sodium are dissolved in 10 ml of methanol in a 100 ml three-necked flask which has been rendered inert using nitrogen. The mixture is warmed to 35 0 C. 1.00 g of 7-bromo-3-methyl-2,3,4,5-tetrahydro 10 1H-1-benzazepin-2-one [reparation in accordance with K. Hino et al., Chem. Pharm. Bull. 36, 2386-2400, 1988] are dissolved in 12 ml of DMF. When the sodium has completely dissolved, the benzazepinone is added. 1.47 g of copper(l) iodide are subsequently added. The reaction mixture is 15 heated to 120 0 C (oil-bath temp.) (reflux) and stirred under these conditions overnight. For work-up, the reaction is cooled to RT. The mixture is filtered through a frit covered with kieselguhr with suction. The frit is rinsed well with DMF. 20 The filtrate is evaporated in a high-vacuum rotary evaporator. The residue is taken up in dichloromethane and extracted with sodium hydroxide solu tion, w = 2%. The aqueous phase is post-extracted with DCM. The com bined organic phases are washed with conc. sodium chloride solution, dried over sodium sulfate, filtered and evaporated to dryness. 25 The residue is triturated with petroleum benzine, filtered off with suction and rinsed well. Yield: 0.6610 g of violet crystals 7-methoxy-3-methyl-2,3,4,5-tetrahydro 1H-1-benzazepin-2-one. 30 1.2 655 mg of 7-methoxy-3-methyl-2,3,4,5-tetrahydro-1 H-1 -benzaze pin-2-one are suspended in 15 ml of toluene in a 100 ml round-bottomed flask. 1.012 g of 2,4-bis(4-phenoxyphenyl)-1,3,2,4-dithiadiphosphetane 35 2,4-disulfide are added. The yellow suspension is heated to reflux with stir ring and boiled for 1.5 h.
WO 2008/052628 ICT/I'P2007/008494 -41 The batch is subsequently poured into ice-water and subjected to conven tional work-up. Yield: 1.5645 g of 7-methoxy-3-methyl-1,3,4,5-tetrahydro-1 -benzazepine 5 2-thione. 1.3 1.5645 g of 7-methoxy-3-methyl-1,3,4,5-tetrahydro-1-benzazepine 2-thione are dissolved in 20 ml of 1-butanol in a 100 ml round-bottomed flask. 1.68 g of 6-methylpyridine-2-carbohydrazide are added. The reaction 10 mixture is heated to reflux and boiled at 120 0 C (oil-bath temp.) overnight. For work-up, the batch is cooled to 40'C with stirring and diluted with 50 ml of ethyl acetate. The red-brown solution is washed three times with 20 ml of semi-conc. sodium chloride solution each time. The organic phase is 15 dried over sodium sulfate, filtered and evaporated to dryness. The residue is taken up in ethyl acetate and extracted twice with 5% citric acid. Finally, the pH of the organic phase is restored to the basic region by shaking with semi-conc. bicarbonate solution. The organic phase is dried 20 over sodium sulfate, filtered and evaporated to dryness. The residue is chromatographed on silica gel. Column conditions: Length: 30 cm diameter: 3.5 cm packing: silica gel 60 (0.04-0.063 mm) 25 Eluent: DCM/methanol, 95:5 585 mg of "Al", El-MS [M+] 320, are obtained 30 1 N "Al" -N 0 N I 35 WO 2008/052628 PCT/IEP2007/008494 -42 H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 7.8 (1H, t), 7.7 (1H,d), 7.3 (1H,d), 7.0 (1H,d), 6.95 (1H,d), 6.8 (1H,dd), 3.85 (3H,s), 2.7 (3H,m), 2.4 (1H,m), 5 2.3 (3H,s), 1.9 (1H,m), 1.3 (3H,br). Example 2 Preparation of 8-hydroxy-4-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H 10 2,3,10b-triazabenzo[e]azulene ("A2") 400 mg of 8-methoxy-4-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3,1Ob-triazabenzo[e]azulene are dissolved in 15 ml of dried dichloro 15 methane in a 100 ml round-bottomed flask. 0.56 ml of boron tribromide is added. The solution is stirred at RT for 4 hours. The batch is then poured into a mixture of ice-water and conc. bicarbonate solution and subjected to conventional work-up. 20 The residue is purified by flash chromatography. Column conditions: Length: 30 cm, diameter: 3.5 cm, packing: silica gel 60 (0.04-0.063 mm) Eluent: DCM/methanol, 95:5 (2 1) 25 305 mg of yellowish oil are obtained. The oil is purified by preparative HPLC, giving 119 mg of "A2" as TFA salt. Content HPLC: 99.6%; HPLC-MS [M+H*] 307; 1 H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 9.7 (1H,s), 7.8 (1H, t), 7.7 (1H,d), 30 7.3 (1H,d), 6.9 (1H,d), 6.8 (1H,d), 6.6 (1H,dd), 2.7 (3H,m), 2.4 (1H,m), 2.3 (3H,s), 1.8 (1H,m), 1.3 (3H,br). Example 3 35 Preparation of 8-fluoro-5-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H- WO 2008/052628 PCT/E P2007/008494 -43 2,3,1 Ob-triazabenzo[e]azulene ("A3") 3.1 1.2884 g of 4-methyl-1,3,4,5-tetrahydro-1-benzazepin-2-one are 5 dissolved in sulfuric acid (20 ml), and the solution is cooled to -10 0 C. HNO 3 (1.6 ml) is then slowly added via a dropping funnel. The mixture is allowed to stir for a further 15 min. The reaction solution is added to ice-water, and the precipitate formed is filtered off and washed well with water, giving 1.3852 g of 4-methyl-7-nitro 10 1,3,4,5-tetrahydro-1-benzazepin-2-one. This substance is dissolved in methanol and hydrogenated (Pd/C 5%), giving 770 mg of 4-methyl-7-amino- 1,3,4,5-tetrahydro-1 -benzazepin-2-one; H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 9.0 (1H,s), 6.6 (1H,d), 6.41 (1H,s), 15 6.39 (1H,d), 4.4 (2H,br), 2.7 (2H,m), 2.4 (1H,m), 2.1 (2H,m), 1.7 (1H,m), 1.0 (3H,d). 3.2 453 mg of nitrosyl tetrafluoroborate are dissolved in 40 ml of dried 20 acetonitrile in a 250 ml three-necked. flask with dropping funnel, thermo meter and drying tube. The solution is cooled to 0*C with stirring. The sus pension of 0.76 g of 4-methyl-7-amino-1,3,4,5-tetrahydro-1-benzazepin-2 one in 20 ml of dried acetonitrile is now added dropwise. The temperature is held between -2 and 0*C using the cold bath. The mixture is stirred at 25 this temperature for a further 45 min. For work-up of the diazonium salt, 100 ml of dried diethyl ether is added to the solution. The mixture is stirred for 30 min. and allowed to warm to RT. The batch solution is concentrated in a rotary evaporator. 30 The oily residue obtained is added in portions to 60 ml of boiling toluene. After the addition, the mixture is boiled under reflux for a further 15 min. The reaction mixture is cooled to RT and filtered through kieselguhr (Celite). The filter cake is rinsed with several portions of chloroform. The 35 filtrate is evaporated to dryness. The crude product is purified by flash chromatography.
WO 2008/052628 ICT/E P2007/008494 - 44 Column conditions: Length: 30 cm, diameter: 3.5 cm, packing: silica gel 60 (0.04-0.063 mm) Eluent: PE/EA, 7:3 (1 I) 5 144 mg of 7-fluoro-4-methyl-1,3,4,5-tetrahydro-1-benzazepin-2-one are obtained; 1 H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 7.1 (1H,dd), 7.05 (1H,m), 6.97 (1H,dd), 2.8 (1H,m), 2.45 (1H,m), 2.3 (2H,m), 2.2 (1H,m), 1.8 (1H,m), 1.0 (3H,d). 10 3.3 Reaction of 144 mg of 7-fluoro-4-methyl-1,3,4,5-tetrahydro-1-benz azepin-2-one, analogously to Example 1, with the modified Lawesson reagent and subsequent conversion into the triazole gives 32 mg of 15 8-fluoro-5-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H-2,3,10b-triaza benzo[ejazulene ("A3"); El-MS [M+] 308; 1 H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 7.8 (2H,m), 7.3 (2H,m), 7.2 (2H,m), 3.1 (1H,br), 2.8 (3H,br), 2.2 (3H,s),1.9 (1H,br), 1.0 (3H,d). 20 Example 4 Preparation of 8-chloro-6-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3,10b-triazabenzo[e]azulene ("A4") 25 2.9 g of 5-methyl-1,3,4,5-tetrahydro-1-benzazepin-2-one are nitrated analogously to Example 3.1. Purification by silica-gel chromatography gives 1.9 g of 5-methyl-7-nitro-1,3,4,5-tetrahydro-1-benzazepin-2-one; H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 10.1 (1H, s), 8.13 (1H,dd), 8.07 30 (1H, d), 7.2 (1H,d), 3.1 (1H,m), 2.2 (3H,s), 1.8 (1H,m), 1.4 (3H,d). The substance is hydrogenated to 5-methyl-7-amino-1,3,4,5-tetrahydro-1 benzazepin-2-one. 35 1.2 g of the amino compound are dissolved in 30 ml of hydrochloric acid and cooled to OC. A cold solution of sodium nitrite (439.1 mg) in water is WO 2008/052628 PCT/E P2007/008494 -.45 added dropwise at 0 to 5 0 C. A brown solution forms. When the addition is complete, the mixture is stirred at about 0*C for a further 30 min. A cold solution of Cu(l) chloride (873.5 mg) in 20 ml of hydrochloric acid is added 5 dropwise at 0*C to the diazonium solution prepared. When the addition is complete, the mixture is allowed to warm slowly to RT. For work-up, the reaction solution is taken up in 100 ml of water and washed 3x with ethyl acetate. The combined organic phases are washed 2x with 1 N HCI and with water. The mixture is dried over sodium sulfate, and the solvent is 10 removed in a rotary evaporator, giving 780 mg of 7-chloro-5-methyl 1,3,4,5-tetrahydro-1 -benzazepin-2-one. Further reaction of 250 mg of the product with the modified Lawesson 15 reagent and subsequent reaction with 6-methylpyridine-2-carbohydrazide gives 80 mg of 8-chloro-6-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3,10b-triazabenzo[e]azulene, trifluoroacetate ("A4"); HPLC-MS [M+H+] 325. 20 The following compounds are obtained analogously to the above exam ples No. Name and/or structure MS 25 "A5" 8-Hydroxy-6-methyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro- El-MS [M+] 4H-2,3,10b-triazabenzo[e]azulene, trifluoroacetate 306 HO 30 -N
N
N N 'H-NMR (500 MHz, DMSO-d 6 ) 6 [pm]: 9.7 (1H,s), 7.9 (1H, 35 t), 7.6 (1H,d), 7.55 (1H,d), 7.1 (1H,d). 6.9 (1H,d), 6.7 (1H,dd), 3.2 (1H,m), 2.9 (1H,m), 2.5 (1H,m), 2.45 (3H,s), 2.4 (1H,m), 1.9 (1H,m), 1.3 (3H,br) WO 2008/052628 PCT/E P2007/008494 -46 "A6" 1-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-2, 3,1 Ob-triaza- El-MS [M] benzo[e]azulene, trifluoroacetate 276 5 N N NN N "AT 8-Bromo-4-methyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H- El-MS [M'] 2,3,1Ob-triazabenzo[e]azulene 369 10 Br 1N N N 15N "A8" 4-Methyl-i -(6-methylpyridin-2-yl)-5,6-dihydro-4H-2,3, 1 Ob- El-MS [M'J triazabenzo[e]azulene, bistrifluoroacetate 290 "A9" 6-Methyl-i -(6-methylpyridin-2-y)-5,6-dihydro-4H-2,3,10b- HPLC-MS 20 triazabenzo[e]azulenes [M+H*] 291 "A1 0" 8-Bromo-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H-2,3,10b- HPLC-MS triazabenzo[e]azulene, trifluoroacetate [M+H*] 356 "All" 8-Bromo-5-methyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H- H PLC-MS 25 2,3,1Ob-triazabenzo[e]azulene [M+H*] 370 "A12" 7-Methoxy-l -(6-methylpyridin-2-yl)-5,6-dihydro-4H-2.3, 1Ob- El-MS [M'] triazabenzo[e]azulene 306 "Al 3" 7-Hydroxy-l -(6-methylpyridin-2-yI)-5,6-dihydro-4H-2,3,1 Ob- HPLC-MS triazabenzo[e]azulene [M+H*] 293 30 "A14" 8-Cyano-4-methyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H- El-MS [M-] 2,3,10b-triazabenzo[e]azulene, trifluoroacetate 315 "Al 5" 8-Cyano-5-methyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H- HPLC-MS 2,3,10b-triazabenzo[e]azulene, trifluoroacetate [M+H*] 316 35 "Al 6" 7-Acetoxy-1 -(6-rnethylpyridin-2-yl)-5,6-dihydro-4H-2,3, 1Ob- HPLC-MS triazabenzo[e]azulene [M+H'] 335 WO 2008/052628 rcri- 112007/00I849)4 -47 "A 17" 8-Chloro-5-methyl-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H- H PLCf-WS 2,3, 1lOb-triazabenzo[e]azulene [M+H 4 ] 325 "A 18"1 8-Methoxy-6-methyl-1 -(6-m ethyl pyri d in-2-yI)-5,6-d ih yd ro- H PLC-MS 4H-2,3, 1 b-triazabenzo[e]azulene, trifluoroacetate [M+H 1 ] 321 5"Al 9" 8-Hydroxy-4-ethyl-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H 2,3, 1 Ob-triazabenzo[e]azulene "A2011 8-Hydroxy-4-propyl-1 -(6-methylpyridin-2-yI)-5,6-dihydro 4H-2, 3, 1 Ob-triazabenzo[e]azulene 10 "A21" 8-Hydroxy-4-isobutyl- 1 -(6-methylpyridin-2-yI)-5 ,6-dihydro 4H-2, 3, 1 Ob-triazabenzo[e]azulene 15 20 25 30 35 WO 2008/052628 PCT/E P2007/008494 - 48 The following examples relate to medicaments: 5 Example A: Injection vials A solution of 100 g of an active ingredient of the formula I and 5 g of diso dium hydrogenphosphate in 3 1 of bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid, sterile filtered, transferred into injection vials, 10 lyophilised under sterile conditions and sealed under sterile conditions. Each injection vial contains 5 mg of active ingredient. Example B: Suppositories 15 A mixture of 20 g of an active ingredient of the formula I with 100 g of soya lecithin and 1400 g of cocoa butter is melted, poured into moulds and allowed to cool. Each suppository contains 20 mg of active ingredient 20 Example C: Solution A solution is prepared from 1 g of an active ingredient of the formula I, 9.38 g of NaH 2
PO
4 2 H 2 0, 28.48 g of Na 2
HPO
4 - 12 H 2 0 and 0.1 g of 25 benzalkonium chloride in 940 ml of bidistilled water. The pH is adjusted to 6.8, and the solution is made up to 1 1 and sterilised by irradiation. This solution can be used in the form of eye drops. 30 Example D: Ointment 500 mg of an active ingredient of the formula I are mixed with 99.5 g of Vaseline under aseptic conditions. 35 WO 2008/052628 PCT/EP20071008494 -49 Example E: Tablets A mixture of 1 kg of active ingredient of the formula 1, 4 kg of lactose, 5 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is pressed in a conventional manner to give tablets in such a way that each tablet contains 10 mg of active ingredient. Example F: Dragees 10 Tablets are pressed analogously to Example E and subsequently coated in a conventional manner with a coating of sucrose, potato starch, talc, traga canth and dye. 15 Example G: Capsules 2 kg of active ingredient of the formula I are introduced into hard gelatine 20 capsules in a conventional manner in such a way that each capsule con tains 20 mg of the active ingredient. Example H: Ampoules 25 A solution of 1 kg of active ingredient of the formula I in 60 I of bidistilled water is sterile filtered, transferred into ampoules, lyophilised under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient. 30 35

权利要求:
Claims (14)
[1] 1. Compounds of the formula 1 5 N R3 I N N N 10 R 1 in which R1 denotes H, A, OH, OA, NO 2 , NH 2 , NHA, NA 2 , Hal, CN, 15 A-COO, COOH, COOA or CONR 4 R 5 , 2 3 R , R each, independently of one another, denote H. A. alkenyl having 2-6 C atoms, alkynyl having 2-6 C atoms or Hal, 20 R 4 , R 5 each, independently of one another, denote H or A. A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 C atoms, in which 1-7 H atoms may be replaced by F, Hal denotes F, Cl, Br or I, 25 and pharmaceutically usable derivatives, solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
[2] 2. Compounds according to Claim 1 in which 30 Ri denotes H, OH, OA, Hal, CN or A-COO, and pharmaceutically usable derivatives, solvates, salts and stereo isomers thereof, including mixtures thereof in all ratios. 35
[3] 3. Compounds according to Claim 1 or 2 in which R 2 denotes H or A. WO 2008/052628 PC'/E P2007/008494 - 51 and pharmaceutically usable derivatives, solvates, salts and stereo isomers thereof, including mixtures thereof in all ratios. 5
[4] 4. Compounds according to Claim 1, 2 or 3 in which R 3 denotes A, and pharmaceutically usable derivatives, solvates, salts and stereo isomers thereof, including mixtures thereof in all ratios. 10
[5] 5. Compounds according to one or more of Claims 1-4 in which A unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which 1-5 H atoms may be replaced by F, and pharmaceutically usable derivatives, solvates, salts and stereo 15 isomers thereof, including mixtures thereof in all ratios.
[6] 6. Compounds according to one or more of Claims 1-5 in which R' denotes H, OH, OA, Hal, CN or A-COO, 20 R 2 denotes H or A, R 3 denotes A, A denotes unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 C atoms, in which 1-5 H atoms may be replaced by F, 25 Hal denotes F, Cl, Br or I, and pharmaceutically usable derivatives, solvates, salts and stereo isomers thereof, including mixtures thereof in all ratios. 30
[7] 7. Compounds according to Claim 1 selected from the group 35 WO 2008/052628 PCI'/EPI20071008494 - 52 No. Name and/or structure- 7 "All'
[8] 8-Meth oxy-4-m ethyl- 1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3, 1 Ob-triazabenzo[e]azulene 5 ll~~A2t" 8-Hydroxy-4-methyl- 1 -(6-m ethyl pyrid in-2-yI) -5, 6-dih yd ro-4 H 2,3,1 Ob-triazabenzo[e]azulene 1___ 8-Fluoro-5-methyl-1 -(6-methylpyridin-2-yI)-5, 6-dihydro-4H- 2,3, 1 Ob-triazabenzo[elazulene "A411 8-Chloro-6-methyl-1 -(6-methylpyridin-2-yI)-5, 6-dihydro-4H 10 2,3, 1 Ob-triazabenzo[e]azulene---- "lAS" 8-Hydroxy-6-methyl-l1-(6-methylpyridin-2-yI)-5, 6-dihydro-4 H 2,3,1 Ob-triazabenzo[e]azulene, trifluoroacetate HO 15 __ N N K N N llA6 1 -(6-Methylpyridin-2-yl)-5,6-dihydro-4H-2,3, 1 Ob-triaza 20 benzo[e]azulene, trifluoroacetate N N 25 N" "1A7 8-Bromo-4-methyl-l1-(6-methylpyridin-2-yi)-5, 6-dihydro-4H 2,3, 1 Ob-triazabenzo[elazulene 30 Br,. N ,N 35 "A" 4-MethyI-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H-2,3, 1 Ob5trTi {________azabenzo[e]azulene, bistrifluoroacetate WO 2008/052628 PCT/FP2007/008494 -53 "A9" 6-Methyl-i -(6-methylpyridin-2-yl)-5,6-dihydro-4H-2,3, 1 Ob-tri azabenzo[e]azulenes "A10" 8-Bromo-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H-2,3,10b-trk azabe nzoje]azulene, trifluoroacetate 5 "All" 8-Bromo-5-methyl-1.-(6-methylpyridin-2-yI)-5,6-dihydro-4H 2,3, 1 Ob-triazabenzo[e]azulene "A12" 7-Methoxy-1 -(6-methyipyridin-2-yl)-5,6-dihydro-4H-2,3, 1 Ob triazabenzo[e]azulene 10 "A13" 7-Hydroxy-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H-2,3, 1 Ob triazabenzo[e]azulene "A14" 8-Cyano-4-rethyl-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H 2,3,1 Ob-triazabenzo[elazulene, trifluoroacetate "A 15"1 8-Cya no-5-meth yl- 1 -(6-m ethyl pyrid in -2-yI)-5,6-d ih yd ro-4 H 15 2,3,1 Ob-triazabenzo[elazulene, trifluoroacetate "A16" 7-Acetoxy-1 -(6-methylpyridin-2-yi)-5,6-dihydro-4H-2,3,1 Ob I triazabenzo[e]azulene "A17" 8-Chloro-5-methyl-1-(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3, 1 Ob-triazabenzo[e]azulene 20 "A18" 8-Methoxy-6-methyl-1 -(6-methypyridin-2-yI)-5,6-dihydro-4H 2,3,1 Ob-triazabenzo[e]azulene, trifluoroacetate "A 19" 8-Hydroxy-4-ethyl--(6-methylpyridin-2-yI)-5,6-dihydro-4H- 2,3,1 Ob-triazabenzo[e]azulene 25 "A20" 8-Hydroxy-4-propyl-1 -(6-methylpyridin-2-yl)-5,6-dihydro-4H 2,3,1 Ob-triazabenzo[e]azulene "A2 V" 8-Hydroxy-4-isobutyl-1 -(6-methylpyridin-2-yI)-5,6-dihydro-4H 2,3,1 Ob-triazabenzo[e]azulene 30 - - _ _ _ _ _ _ _ _ _ _ and pharmaceutically usable derivatives, solvates, salts and stereo isomers thereof, including mixtures thereof in all ratios. 35 WO 2008/052628 PCT/E P2007/008494 - 54 8. Process for the preparation of compounds of the formula I according to Claims 1-7 and pharmaceutically usable derivatives, salts, sol vates, tautomers and stereoisomers thereof, characterised in that 5 a) a compound of the formula Il H S N 10 R1 R2 in which R1 and R2 has the meaning indicated in Claim 1, 15 is reacted with a compound of the formula IlIl - N R3 H || 20 , NNH2 0 in which R 3 has the meaning indicated in Claim 1, 25 or b) a radical R 1 is converted into another radical R1 by cleaving 30 an ether, and/or a base or acid of the formula I is converted into one of its salts. 35
[9] 9. Medicament comprising at least one compound of the formula I according to one or more of Claims 1 to 7 and/or pharmaceutically WO 2008/052628 iCT/E'P2007/0(08494 - 55 usable derivatives, solvates, salts and stereoisomers thereof, includ ing mixtures thereof in all ratios, and optionally excipients and/or adjuvants. 5
[10] 10. Use of compounds according to one or more of Claims 1 to 7 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment and/or com 10 bating of cancer, tumour growth, metastatic growth, fibrosis, resteno sis, HIV infection, Alzheimer's, atherosclerosis, and/or for promoting wound healing. 15
[11] 11. Use according to Claim 10, where the tumour is selected from the group of tumours of the squamous epithelium, the bladder, the stom ach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital 20 tract, the lymphatic system, the stomach, the larynx, the lung, lung adenocarcinoma, small-cell lung carcinoma, pancreatic cancer, glio blastoma, colon carcinoma, breast carcinoma, tumour of the blood and immune system, acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia. 25
[12] 12. Use of compounds according to Claim 10 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, 30 where a therapeutically effective amount of a compound of the for mula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modu lator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiprolif 35 erative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitor. WO 2008/052628 PCT/EP2007/008494 - 56
[13] 13. Use of compounds according to Claim 10 and/or physiologically acceptable salts and solvates thereof for the preparation of a medica 5 ment for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative 10 agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) further angiogenesis inhibitor, 15
[14] 14. Medicament comprising at least one compound of the formula I according to one or more of Claims 1 to 7 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament 20 active ingredient. 25 30 35

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2006334899B2|2012-06-07|Triazole derivatives

---

US20110028472A1|2011-02-03|Thienopyrimidines

---

AU2008314245B2|2013-07-18|5-cyano-thienopyridines for the treatment of tumors

---

EP2307425B1|2014-03-26|Imidazothiadiazoles derivatives

---

AU2007315374B2|2012-07-26|Triazabenzo[e]azulene derivatives for the treatment of tumors

---

US20120101095A1|2012-04-26|Alkoxy-thienopyrimidines as tgf-beta receptor kinase modulators

同族专利:

---

公开号 | 公开日

---

ES2354483T3|2011-03-15|

---

US20100063028A1|2010-03-11|

---

DE102006051796A1|2008-05-08|

---

JP2010508311A|2010-03-18|

---

CA2668562A1|2008-05-08|

---

IL198465D0|2010-02-17|

---

CA2668562C|2015-03-31|

---

US8063040B2|2011-11-22|

---

EP2111403A1|2009-10-28|

---

JP5296698B2|2013-09-25|

---

AU2007315374A8|2009-07-09|

---

IL198465A|2014-03-31|

---

AT487721T|2010-11-15|

---

DE502007005636D1|2010-12-23|

---

WO2008052628A1|2008-05-08|

---

EP2111403B1|2010-11-10|

---

AU2007315374B2|2012-07-26|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

DE2318673A1|1973-04-13|1974-11-07|Boehringer Sohn Ingelheim|NEW SUBSTITUTED TRIAZOLO-1,5BENZODIAZEPINE|

---

JP4409680B2|1999-10-18|2010-02-03|株式会社ヤクルト本社|Tricyclic fused imidazole derivatives|

---

AU2006269496A1|2005-07-06|2007-01-18|Liebert Corporation|Maximized battery run-time in a parallel UPS system|

---

DE102005061840A1|2005-12-23|2007-06-28|Merck Patent Gmbh|New polyaza-benzo-azulene compounds are transforming growth factor-beta receptor kinase inhibitors used for treating e.g. cancer, HIV infection and Alzheimer's disease|KR20170042821A|2014-05-09|2017-04-19|피메라, 아이엔씨.|Novel compositions, uses and methods for making them|

---

CN107108512B|2014-10-10|2021-05-04|基因泰克公司|Therapeutic compounds and uses thereof|

---

CN106349241B|2015-07-15|2020-04-21|上海翰森生物医药科技有限公司|Triazole derivative with HSP90 inhibitory activity and preparation method and application thereof|

---

CN107540672A|2017-10-10|2018-01-05|牡丹江医学院|A kind of medicine and its synthetic method for treating hepatic sclerosis|

---

TW201938171A|2017-12-15|2019-10-01|匈牙利商羅特格登公司|Tricyclic compounds as vasopressin V1a receptor antagonists|

---

HU231206B1|2017-12-15|2021-10-28|Richter Gedeon Nyrt|Triazolobenzazepines|

法律状态:
2009-07-09| TH| Corrigenda|Free format text: IN VOL 23, NO 24, PAGE(S) 8771 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME MERCK PATENT GMBH, APPLICATION NO. 2007315374, UNDER INID (54) CORRECT THE TITLE TO READ TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS |

---

2012-11-22| FGA| Letters patent sealed or granted (standard patent)|

---

2016-04-21| MK14| Patent ceased section 143(a) (annual fees not paid) or expired|

优先权:

---

申请号 | 申请日 | 专利标题

---

DE102006051796A|DE102006051796A1|2006-11-03|2006-11-03|Triaza-benzo [e] azulene derivatives|

---

DE102006051796.2||2006-11-03||

---

PCT/EP2007/008494|WO2008052628A1|2006-11-03|2007-09-29|Triazabenzo[e]azulene derivatives for the treatment of tumors|

---